{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T03:55:33Z","timestamp":1785815733126,"version":"3.56.0"},"reference-count":189,"publisher":"Impact Journals, LLC","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aging"],"published-print":{"date-parts":[[2024,6,15]]},"DOI":"10.18632\/aging.205858","type":"journal-article","created":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T17:22:55Z","timestamp":1716484975000},"page":"10165-10196","source":"Crossref","is-referenced-by-count":12,"title":["Targeting tumor-associated macrophages to reverse antitumor drug resistance"],"prefix":"10.18632","volume":"16","author":[{"given":"Sheng","family":"Li","sequence":"first","affiliation":[{"name":"The Second Hospital of Jilin University, Changchun, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiyao","family":"Sheng","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary and Pancreatic Surgery, Second Hospital of Jilin University, Changchun, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary and Pancreatic Surgery, Second Hospital of Jilin University, Changchun, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanjiao","family":"Qin","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy, The Second Hospital of Jilin University, Changchun, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2024,5,23]]},"reference":[{"key":"1","doi-asserted-by":"publisher","first-page":"77","DOI":"10.2217\/nnm-2019-0190","article-title":"Depleting tumor-associated Tregs via nanoparticle-mediated hyperthermia to enhance anti-CTLA-4 immunotherapy.","volume":"1","author":"Sun","year":"2020","journal-title":"Nanomedicine (Lond)"},{"key":"2","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1038\/ni.3341","article-title":"The development and maintenance of resident macrophages.","volume":"1","author":"Geissmann","year":"2016","journal-title":"Nat Immunol"},{"key":"3","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.ccell.2015.02.015","article-title":"Macrophages and therapeutic resistance in cancer.","volume":"2","author":"Coussens","year":"2015","journal-title":"Cancer Cell"},{"key":"4","doi-asserted-by":"publisher","first-page":"6995","DOI":"10.3390\/ijms22136995","article-title":"Macrophage Polarization States in the Tumor Microenvironment.","volume":"2","author":"Elsawa","year":"2021","journal-title":"Int J Mol Sci"},{"key":"5","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.it.2019.02.003","article-title":"Targeting Tumor-Associated Macrophages in Cancer.","volume":"4","author":"Varner","year":"2019","journal-title":"Trends Immunol"},{"key":"6","doi-asserted-by":"publisher","first-page":"960","DOI":"10.3390\/cells10040960","article-title":"Tissue-Resident and Recruited Macrophages in Primary Tumor and Metastatic Microenvironments: Potential Targets in Cancer Therapy.","volume":"1","author":"Grossman","year":"2021","journal-title":"Cells"},{"key":"7","doi-asserted-by":"publisher","first-page":"5591","DOI":"10.1242\/jcs.116392","article-title":"The tumor microenvironment at a glance.","volume":"12","author":"Hagemann","year":"2012","journal-title":"J Cell Sci"},{"key":"8","doi-asserted-by":"publisher","first-page":"E4236","DOI":"10.1073\/pnas.1722020115","article-title":"MK2 contributes to tumor progression by promoting M2 macrophage polarization and tumor angiogenesis.","volume":"11","author":"Yaffe","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"9","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.3390\/cancers12082083","article-title":"Stromal CCL2 Signaling Promotes Mammary Tumor Fibrosis through Recruitment of Myeloid-Lineage Cells.","volume":"1","author":"Arendt","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10","doi-asserted-by":"publisher","first-page":"2536","DOI":"10.1084\/jem.20180534","article-title":"Macrophages of distinct origins contribute to tumor development in the lung.","volume":"21","author":"Boissonnas","year":"2018","journal-title":"J Exp Med"},{"key":"11","doi-asserted-by":"publisher","first-page":"7022","DOI":"10.1158\/0008-5472.CAN-04-1449","article-title":"A paracrine loop between tumor cells and macrophages is required for tumor cell migration in mammary tumors.","volume":"6","author":"Condeelis","year":"2004","journal-title":"Cancer Res"},{"key":"12","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.1158\/0008-5472.CAN-06-1823","article-title":"Direct visualization of macrophage-assisted tumor cell intravasation in mammary tumors.","volume":"6","author":"Condeelis","year":"2007","journal-title":"Cancer Res"},{"key":"13","doi-asserted-by":"publisher","first-page":"12150","DOI":"10.1038\/ncomms12150","article-title":"Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards.","volume":"7","author":"Umansky","year":"2016","journal-title":"Nat Commun"},{"key":"14","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.ccell.2016.05.017","article-title":"The Multifaceted Role of Perivascular Macrophages in Tumors.","volume":"3","author":"Pollard","year":"2016","journal-title":"Cancer Cell"},{"key":"15","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1158\/2159-8290.CD-15-0012","article-title":"Real-Time Imaging Reveals Local, Transient Vascular Permeability, and Tumor Cell Intravasation Stimulated by TIE2hi Macrophage-Derived VEGFA.","volume":"5","author":"Condeelis","year":"2015","journal-title":"Cancer Discov"},{"key":"16","doi-asserted-by":"publisher","first-page":"843","DOI":"10.3390\/ijms22020843","article-title":"The Effect of Hypoxia on the Expression of CXC Chemokines and CXC Chemokine Receptors-A Review of Literature.","volume":"2","author":"Baranowska-Bosiacka","year":"2021","journal-title":"Int J Mol Sci"},{"key":"17","doi-asserted-by":"publisher","first-page":"5812","DOI":"10.1158\/0008-5472.CAN-07-6387","article-title":"The pervasive presence of fluctuating oxygenation in tumors.","volume":"6","author":"Dewhirst","year":"2008","journal-title":"Cancer Res"},{"key":"18","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s10585-006-9024-z","article-title":"Involvement of HIF-1 in invasion of Mum2B uveal melanoma cells.","volume":"2","author":"Agani","year":"2006","journal-title":"Clin Exp Metastasis"},{"key":"19","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1111\/cas.12653","article-title":"Suppression of silent information regulator 1 activity in noncancerous tissues of hepatocellular carcinoma: Possible association with non-B non-C hepatitis pathogenesis.","volume":"10","author":"Maehara","year":"2015","journal-title":"Cancer Sci"},{"key":"20","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1158\/0008-5472.CAN-15-0977","article-title":"Hypoxia-Induced Epithelial-to-Mesenchymal Transition in Hepatocellular Carcinoma Induces an Immunosuppressive Tumor Microenvironment to Promote Metastasis.","volume":"7","author":"Liang","year":"2016","journal-title":"Cancer Res"},{"key":"21","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1182\/blood-2008-12-195941","article-title":"Hypoxia-inducible factors 1 and 2 are important transcriptional effectors in primary macrophages experiencing hypoxia.","volume":"11","author":"Lewis","year":"2009","journal-title":"Blood"},{"key":"22","doi-asserted-by":"publisher","first-page":"10701","DOI":"10.3390\/ijms221910701","article-title":"Chronic and Cycling Hypoxia: Drivers of Cancer Chronic Inflammation through HIF-1 and NF-\u03baB Activation: A Review of the Molecular Mechanisms.","volume":"2","author":"Baranowska-Bosiacka","year":"2021","journal-title":"Int J Mol Sci"},{"key":"23","doi-asserted-by":"publisher","first-page":"5871","DOI":"10.3892\/ol.2019.10956","article-title":"Hypoxia modifies the polarization of macrophages and their inflammatory microenvironment, and inhibits malignant behavior in cancer cells.","volume":"1","author":"Liu","year":"2019","journal-title":"Oncol Lett"},{"key":"24","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/nature13490","article-title":"Functional polarization of tumour-associated macrophages by tumour-derived lactic acid.","volume":"51","author":"Medzhitov","year":"2014","journal-title":"Nature"},{"key":"25","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1200\/JCO.2012.43.4589","article-title":"Gene expression-based model using formalin-fixed paraffin-embedded biopsies predicts overall survival in advanced-stage classical Hodgkin lymphoma.","volume":"3","author":"Fisher","year":"2013","journal-title":"J Clin Oncol"},{"key":"26","doi-asserted-by":"publisher","first-page":"2587","DOI":"10.1158\/1078-0432.CCR-21-3215","article-title":"Predictive Markers of Response to Neoadjuvant Durvalumab with Nab-Paclitaxel and Dose-Dense Doxorubicin\/Cyclophosphamide in Basal-Like Triple-Negative Breast Cancer.","volume":"2","author":"Reisenbichler","year":"2022","journal-title":"Clin Cancer Res"},{"key":"27","doi-asserted-by":"publisher","first-page":"4756","DOI":"10.1158\/1078-0432.CCR-19-3920","article-title":"Multicenter Phase II Study of Cabazitaxel in Advanced Gastroesophageal Cancer: Association of HER2 Expression and M2-Like Tumor-Associated Macrophages with Patient Outcome.","volume":"2","author":"Elmonshed","year":"2020","journal-title":"Clin Cancer Res"},{"key":"28","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1097\/PAI.0000000000000485","article-title":"An Immunoscore Using PD-L1, CD68, and Tumor-infiltrating Lymphocytes (TILs) to Predict Response to Neoadjuvant Chemotherapy in Invasive Breast Cancer.","volume":"2","author":"Fineberg","year":"2018","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"29","doi-asserted-by":"publisher","first-page":"238","DOI":"10.3324\/haematol.2014.113472","article-title":"Prognostic influence of macrophages in patients with diffuse large B-cell lymphoma: a correlative study from a Nordic phase II trial.","volume":"10","author":"Lepp\u00e4","year":"2015","journal-title":"Haematologica"},{"key":"30","doi-asserted-by":"publisher","first-page":"871769","DOI":"10.3389\/fimmu.2022.871769","article-title":"Dissecting Intra-Tumoral Changes Following Immune Checkpoint Blockades in Intrahepatic Cholangiocarcinoma via Single-Cell Analysis.","volume":"1","author":"Qiu","year":"2022","journal-title":"Front Immunol"},{"key":"31","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1001\/jamaoncol.2017.1617","article-title":"Use of PD-1 Targeting, Macrophage Infiltration, and IDO Pathway Activation in Sarcomas: A Phase 2 Clinical Trial.","volume":"4","author":"Ghiringhelli","year":"2018","journal-title":"JAMA Oncol"},{"key":"32","doi-asserted-by":"publisher","first-page":"e451","DOI":"10.1016\/j.cllc.2020.06.016","article-title":"Giant Circulating Cancer-Associated Macrophage-Like Cells Are Associated With Disease Recurrence and Survival in Non-Small-Cell Lung Cancer Treated With Chemoradiation and Atezolizumab.","volume":"2","author":"Lin","year":"2021","journal-title":"Clin Lung Cancer"},{"key":"33","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1038\/s41392-021-00751-9","article-title":"Toripalimab plus chemotherapy as second-line treatment in previously EGFR-TKI treated patients with EGFR-mutant-advanced NSCLC: a multicenter phase-II trial.","volume":"6","author":"Bao","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"34","doi-asserted-by":"publisher","first-page":"786429","DOI":"10.3389\/fimmu.2021.786429","article-title":"Spatial Distribution and Predictive Significance of Dendritic Cells and Macrophages in Esophageal Cancer Treated With Combined Chemoradiotherapy and PD-1 Blockade.","volume":"1","author":"Pang","year":"2021","journal-title":"Front Immunol"},{"key":"35","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1158\/2326-6066.CIR-14-0053","article-title":"Bevacizumab plus ipilimumab in patients with metastatic melanoma.","volume":"2","author":"Murphy","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"36","doi-asserted-by":"publisher","first-page":"6995","DOI":"10.1158\/1078-0432.CCR-19-0101","article-title":"Clinical Efficacy and Tumor Microenvironment Influence in a Dose-Escalation Study of Anti-CD19 Chimeric Antigen Receptor T Cells in Refractory B-Cell Non-Hodgkin's Lymphoma.","volume":"2","author":"Zheng","year":"2019","journal-title":"Clin Cancer Res"},{"key":"37","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/S0140-6736(15)01088-0","article-title":"Antiangiogenic therapy in oncology: current status and future directions.","volume":"38","author":"Harris","year":"2016","journal-title":"Lancet"},{"key":"38","doi-asserted-by":"publisher","first-page":"3749","DOI":"10.1038\/onc.2017.1","article-title":"Macrophage migration inhibitory factor downregulation: a novel mechanism of resistance to anti-angiogenic therapy.","volume":"3","author":"Kohanbash","year":"2017","journal-title":"Oncogene"},{"key":"39","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.18632\/oncotarget.1893","article-title":"Anti-vascular endothelial growth factor therapy-induced glioma invasion is associated with accumulation of Tie2-expressing monocytes.","volume":"5","author":"Gomez-Manzano","year":"2014","journal-title":"Oncotarget"},{"key":"40","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1093\/neuonc\/not082","article-title":"Increase in tumor-associated macrophages after antiangiogenic therapy is associated with poor survival among patients with recurrent glioblastoma.","volume":"1","author":"Chi","year":"2013","journal-title":"Neuro Oncol"},{"key":"41","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1093\/neuonc\/nox081","article-title":"The contribution of tumor-associated macrophages in glioma neo-angiogenesis and implications for anti-angiogenic strategies.","volume":"1","author":"Mustafa","year":"2017","journal-title":"Neuro Oncol"},{"key":"42","doi-asserted-by":"publisher","first-page":"7905","DOI":"10.1158\/0008-5472.CAN-09-2099","article-title":"Direct evidence that bevacizumab, an anti-VEGF antibody, up-regulates SDF1alpha, CXCR4, CXCL6, and neuropilin 1 in tumors from patients with rectal cancer.","volume":"6","author":"Clark","year":"2009","journal-title":"Cancer Res"},{"key":"43","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1038\/nrclinonc.2011.21","article-title":"Antiangiogenic therapy: impact on invasion, disease progression, and metastasis.","volume":"8","author":"Kerbel","year":"2011","journal-title":"Nat Rev Clin Oncol"},{"key":"44","doi-asserted-by":"publisher","first-page":"7631","DOI":"10.18632\/oncotarget.24146","article-title":"S100A9MDSC and TAM-mediated EGFR-TKI resistance in lung adenocarcinoma: the role of","volume":"9","author":"Lin","year":"2018","journal-title":"Oncotarget"},{"key":"45","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.immuni.2014.06.010","article-title":"Tumor-associated macrophages: from mechanisms to therapy.","volume":"4","author":"Pollard","year":"2014","journal-title":"Immunity"},{"key":"46","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.it.2015.02.004","article-title":"Macrophages and cancer: from mechanisms to therapeutic implications.","volume":"3","author":"Natoli","year":"2015","journal-title":"Trends Immunol"},{"key":"47","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1038\/nm.3291","article-title":"An interleukin-17-mediated paracrine network promotes tumor resistance to anti-angiogenic therapy.","volume":"1","author":"Ferrara","year":"2013","journal-title":"Nat Med"},{"key":"48","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1038\/nbt1323","article-title":"Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells.","volume":"2","author":"Ferrara","year":"2007","journal-title":"Nat Biotechnol"},{"key":"49","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1038\/nature06348","article-title":"Bv8 regulates myeloid-cell-dependent tumour angiogenesis.","volume":"45","author":"Tan","year":"2007","journal-title":"Nature"},{"key":"50","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1158\/2159-8290.CD-15-0819","article-title":"Cancer Metastasis: Perivascular Macrophages Under Watch.","volume":"5","author":"De Palma","year":"2015","journal-title":"Cancer Discov"},{"key":"51","doi-asserted-by":"publisher","first-page":"11085","DOI":"10.1038\/s41598-019-47438-4","article-title":"Increased Antiangiogenic Effect by Blocking CCL2-dependent Macrophages in a Rodent Glioblastoma Model: Correlation Study with Dynamic Susceptibility Contrast Perfusion MRI.","volume":"9","author":"Choi","year":"2019","journal-title":"Sci Rep"},{"key":"52","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/nature10138","article-title":"CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis.","volume":"47","author":"Pollard","year":"2011","journal-title":"Nature"},{"key":"53","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1038\/sj.bjc.6603240","article-title":"Clodronate-liposome-mediated depletion of tumour-associated macrophages: a new and highly effective antiangiogenic therapy approach.","volume":"9","author":"Schwendener","year":"2006","journal-title":"Br J Cancer"},{"key":"54","doi-asserted-by":"publisher","first-page":"3420","DOI":"10.1158\/1078-0432.CCR-09-2904","article-title":"Depletion of tumor-associated macrophages enhances the effect of sorafenib in metastatic liver cancer models by antimetastatic and antiangiogenic effects.","volume":"1","author":"Tang","year":"2010","journal-title":"Clin Cancer Res"},{"key":"55","doi-asserted-by":"publisher","first-page":"E227","DOI":"10.1002\/ijc.27403","article-title":"Tumor-associated macrophages correlate with response to epidermal growth factor receptor-tyrosine kinase inhibitors in advanced non-small cell lung cancer.","volume":"13","author":"Kuo","year":"2012","journal-title":"Int J Cancer"},{"key":"56","doi-asserted-by":"publisher","first-page":"2450","DOI":"10.1093\/annonc\/mdv474","article-title":"Variations in genes regulating tumor-associated macrophages (TAMs) to predict outcomes of bevacizumab-based treatment in patients with metastatic colorectal cancer: results from TRIBE and FIRE3 trials.","volume":"2","author":"Parekh","year":"2015","journal-title":"Ann Oncol"},{"key":"57","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s12032-014-0127-0","article-title":"M2-polarized macrophages contribute to the decreased sensitivity of EGFR-TKIs treatment in patients with advanced lung adenocarcinoma.","volume":"3","author":"Gao","year":"2014","journal-title":"Med Oncol"},{"key":"58","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1158\/1078-0432.CCR-21-3202","article-title":"Tumor Immunogenomic Features Determine Outcomes in Patients with Metastatic Colorectal Cancer Treated with Standard-of-Care Combinations of Bevacizumab and Cetuximab.","volume":"2","author":"Vincent","year":"2022","journal-title":"Clin Cancer Res"},{"key":"59","doi-asserted-by":"publisher","first-page":"5668","DOI":"10.1158\/1078-0432.CCR-11-0239","article-title":"Activation of tumor-promoting type 2 macrophages by EGFR-targeting antibody cetuximab.","volume":"1","author":"van Hall","year":"2011","journal-title":"Clin Cancer Res"},{"key":"60","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1158\/1078-0432.CCR-14-1993","article-title":"Correlation of PD-L1 tumor expression and treatment outcomes in patients with renal cell carcinoma receiving sunitinib or pazopanib: results from COMPARZ, a randomized controlled trial.","volume":"2","author":"Motzer","year":"2015","journal-title":"Clin Cancer Res"},{"key":"61","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1158\/2159-8290.CD-18-0957","article-title":"Transcriptomic Profiling of the Tumor Microenvironment Reveals Distinct Subgroups of Clear Cell Renal Cell Cancer: Data from a Randomized Phase III Trial.","volume":"9","author":"Patel","year":"2019","journal-title":"Cancer Discov"},{"key":"62","doi-asserted-by":"publisher","first-page":"2784","DOI":"10.1073\/pnas.1018866109","article-title":"Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia.","volume":"10","author":"Wicha","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"63","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1038\/nrclinonc.2011.83","article-title":"Antiangiogenic therapy, hypoxia, and metastasis: risky liaisons, or not?","volume":"8","author":"Carmeliet","year":"2011","journal-title":"Nat Rev Clin Oncol"},{"key":"64","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.ccell.2014.10.006","article-title":"Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia.","volume":"2","author":"Jain","year":"2014","journal-title":"Cancer Cell"},{"key":"65","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1002\/ijc.28686","article-title":"Anti-VEGF antibody therapy induces tumor hypoxia and stanniocalcin 2 expression and potentiates growth of human colon cancer xenografts.","volume":"13","author":"Konno","year":"2014","journal-title":"Int J Cancer"},{"key":"66","doi-asserted-by":"publisher","first-page":"3672","DOI":"10.1172\/JCI84427","article-title":"The impact of hypoxia on tumor-associated macrophages.","volume":"12","author":"Mazzone","year":"2016","journal-title":"J Clin Invest"},{"key":"67","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/nrc3183","article-title":"HIF1\u03b1 and HIF2\u03b1: sibling rivalry in hypoxic tumour growth and progression.","volume":"1","author":"Simon","year":"2011","journal-title":"Nat Rev Cancer"},{"key":"68","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/ncb3330","article-title":"The ever-expanding role of HIF in tumour and stromal biology.","volume":"1","author":"Giaccia","year":"2016","journal-title":"Nat Cell Biol"},{"key":"69","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1182\/blood-2004-03-1109","article-title":"Mechanisms regulating the recruitment of macrophages into hypoxic areas of tumors and other ischemic tissues.","volume":"10","author":"Lewis","year":"2004","journal-title":"Blood"},{"key":"70","doi-asserted-by":"publisher","first-page":"12000","DOI":"10.1038\/s41598-018-30437-2","article-title":"Gemcitabine treatment promotes immunosuppressive microenvironment in pancreatic tumors by supporting the infiltration, growth, and polarization of macrophages.","volume":"8","author":"Singh","year":"2018","journal-title":"Sci Rep"},{"key":"71","doi-asserted-by":"publisher","first-page":"e1436922","DOI":"10.1080\/2162402X.2018.1436922","article-title":"Tumor-associated macrophages in human breast cancer produce new monocyte attracting and pro-angiogenic factor YKL-39 indicative for increased metastasis after neoadjuvant chemotherapy.","volume":"7","author":"Flatley","year":"2018","journal-title":"Oncoimmunology"},{"key":"72","doi-asserted-by":"publisher","first-page":"1758835919854238","DOI":"10.1177\/1758835919854238","article-title":"Phase Ib study of the combination of pexidartinib (PLX3397), a CSF-1R inhibitor, and paclitaxel in patients with advanced solid tumors.","volume":"1","author":"Rugo","year":"2019","journal-title":"Ther Adv Med Oncol"},{"key":"73","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1158\/0008-5472.CAN-19-1676","article-title":"Heparanase and Chemotherapy Synergize to Drive Macrophage Activation and Enhance Tumor Growth.","volume":"8","author":"Vlodavsky","year":"2020","journal-title":"Cancer Res"},{"key":"74","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1093\/neuonc\/nos158","article-title":"Glioblastoma resistance to anti-VEGF therapy is associated with myeloid cell infiltration, stem cell accumulation, and a mesenchymal phenotype.","volume":"1","author":"de Groot","year":"2012","journal-title":"Neuro Oncol"},{"key":"75","doi-asserted-by":"publisher","first-page":"5350","DOI":"10.18632\/oncotarget.2110","article-title":"Macrophages are recruited to hypoxic tumor areas and acquire a pro-angiogenic M2-polarized phenotype via hypoxic cancer cell derived cytokines Oncostatin M and Eotaxin.","volume":"5","author":"Bhadauria","year":"2014","journal-title":"Oncotarget"},{"key":"76","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1053\/j.gastro.2016.02.040","article-title":"Tumor-Associated Neutrophils Recruit Macrophages and T-Regulatory Cells to Promote Progression of Hepatocellular Carcinoma and Resistance to Sorafenib.","volume":"15","author":"Zhou","year":"2016","journal-title":"Gastroenterology"},{"key":"77","doi-asserted-by":"publisher","first-page":"114113","DOI":"10.1016\/j.bcp.2020.114113","article-title":"Galectin-3 expression and secretion by tumor-associated macrophages in hypoxia promotes breast cancer progression.","volume":"17","author":"Guo","year":"2020","journal-title":"Biochem Pharmacol"},{"key":"78","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.addr.2017.04.010","article-title":"Progress in tumor-associated macrophage (TAM)-targeted therapeutics.","volume":"11","author":"Pun","year":"2017","journal-title":"Adv Drug Deliv Rev"},{"key":"79","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.18632\/oncotarget.663","article-title":"Modulating antiangiogenic resistance by inhibiting the signal transducer and activator of transcription 3 pathway in glioblastoma.","volume":"3","author":"Heimberger","year":"2012","journal-title":"Oncotarget"},{"key":"80","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.celrep.2015.03.055","article-title":"Intratumoral myeloid cells regulate responsiveness and resistance to antiangiogenic therapy.","volume":"1","author":"Bergers","year":"2015","journal-title":"Cell Rep"},{"key":"81","doi-asserted-by":"publisher","first-page":"2480","DOI":"10.1158\/0008-5472.CAN-12-3542","article-title":"Chemotherapy alters monocyte differentiation to favor generation of cancer-supporting M2 macrophages in the tumor microenvironment.","volume":"7","author":"van der Burg","year":"2013","journal-title":"Cancer Res"},{"key":"82","doi-asserted-by":"publisher","first-page":"4326","DOI":"10.1073\/pnas.1819473116","article-title":"Reactive oxygen species modulate macrophage immunosuppressive phenotype through the up-regulation of PD-L1.","volume":"11","author":"Pujana","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"83","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41389-021-00359-2","article-title":"Dissecting the single-cell transcriptome network in patients with esophageal squamous cell carcinoma receiving operative paclitaxel plus platinum chemotherapy.","volume":"1","author":"Tan","year":"2021","journal-title":"Oncogenesis"},{"key":"84","doi-asserted-by":"publisher","first-page":"14482","DOI":"10.1038\/s41598-019-50848-z","article-title":"Extracellular Vesicles Shedding Promotes Melanoma Growth in Response to Chemotherapy.","volume":"9","author":"Chammas","year":"2019","journal-title":"Sci Rep"},{"key":"85","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1111\/jcmm.12004","article-title":"Hypoxia-inducing factors as master regulators of stemness properties and altered metabolism of cancer- and metastasis-initiating cells.","volume":"1","author":"Batra","year":"2013","journal-title":"J Cell Mol Med"},{"key":"86","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41416-019-0482-x","article-title":"M2 macrophages mediate sorafenib resistance by secreting HGF in a feed-forward manner in hepatocellular carcinoma.","volume":"12","author":"Li","year":"2019","journal-title":"Br J Cancer"},{"key":"87","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1200\/JCO.2011.38.7621","article-title":"Targeting the angiopoietin\/Tie2 pathway: cutting tumor vessels with a double-edged sword?","volume":"3","author":"Heymach","year":"2012","journal-title":"J Clin Oncol"},{"key":"88","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1038\/nrc2894","article-title":"Targeting the ANGPT-TIE2 pathway in malignancy.","volume":"1","author":"Lappe","year":"2010","journal-title":"Nat Rev Cancer"},{"key":"89","doi-asserted-by":"publisher","first-page":"5270","DOI":"10.1158\/0008-5472.CAN-10-0012","article-title":"Angiopoietin-2 regulates gene expression in TIE2-expressing monocytes and augments their inherent proangiogenic functions.","volume":"7","author":"Lewis","year":"2010","journal-title":"Cancer Res"},{"key":"90","doi-asserted-by":"publisher","first-page":"3479","DOI":"10.1158\/0008-5472.CAN-14-3587","article-title":"Perivascular M2 Macrophages Stimulate Tumor Relapse after Chemotherapy.","volume":"7","author":"De Palma","year":"2015","journal-title":"Cancer Res"},{"key":"91","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.canlet.2011.08.008","article-title":"Endostar enhances the antineoplastic effects of combretastatin A4 phosphate in an osteosarcoma xenograft.","volume":"31","author":"Zheng","year":"2011","journal-title":"Cancer Lett"},{"key":"92","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.1200\/JCO.2003.05.185","article-title":"Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results.","volume":"2","author":"Price","year":"2003","journal-title":"J Clin Oncol"},{"key":"93","doi-asserted-by":"publisher","first-page":"3428","DOI":"10.1158\/1078-0432.CCR-11-3376","article-title":"Phase I trial of combretastatin A4 phosphate (CA4P) in combination with bevacizumab in patients with advanced cancer.","volume":"1","author":"Lu","year":"2012","journal-title":"Clin Cancer Res"},{"key":"94","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1172\/JCI44562","article-title":"TIE2-expressing macrophages limit the therapeutic efficacy of the vascular-disrupting agent combretastatin A4 phosphate in mice.","volume":"12","author":"Lewis","year":"2011","journal-title":"J Clin Invest"},{"key":"95","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.4049\/jimmunol.2000185","article-title":"Hypoxia-Inducible Factor \u03b1 Subunits Regulate Tie2-Expressing Macrophages That Influence Tumor Oxygen and Perfusion in Murine Breast Cancer.","volume":"20","author":"Marsh","year":"2020","journal-title":"J Immunol"},{"key":"96","doi-asserted-by":"publisher","first-page":"16146","DOI":"10.18632\/oncotarget.7550","article-title":"Soluble Tie2 overrides the heightened invasion induced by anti-angiogenesis therapies in gliomas.","volume":"7","author":"Gomez-Manzano","year":"2016","journal-title":"Oncotarget"},{"key":"97","doi-asserted-by":"publisher","first-page":"4183","DOI":"10.4049\/jimmunol.1002802","article-title":"Angiopoietin 2 stimulates TIE2-expressing monocytes to suppress T cell activation and to promote regulatory T cell expansion.","volume":"18","author":"Lewis","year":"2011","journal-title":"J Immunol"},{"key":"98","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.coph.2017.05.009","article-title":"Can the co-dependence of the immune system and angiogenesis facilitate pharmacological targeting of tumours?","volume":"3","author":"Noonan","year":"2017","journal-title":"Curr Opin Pharmacol"},{"key":"99","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s10456-017-9552-y","article-title":"Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy?","volume":"2","author":"Duda","year":"2017","journal-title":"Angiogenesis"},{"key":"100","doi-asserted-by":"publisher","first-page":"7034","DOI":"10.1158\/1078-0432.CCR-17-0647","article-title":"Macrophages Facilitate Resistance to Anti-VEGF Therapy by Altered VEGFR Expression.","volume":"2","author":"Wu","year":"2017","journal-title":"Clin Cancer Res"},{"key":"101","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.ccr.2011.02.005","article-title":"Targeting the ANG2\/TIE2 axis inhibits tumor growth and metastasis by impairing angiogenesis and disabling rebounds of proangiogenic myeloid cells.","volume":"1","author":"De Palma","year":"2011","journal-title":"Cancer Cell"},{"key":"102","doi-asserted-by":"publisher","first-page":"e1408745","DOI":"10.1080\/2162402X.2017.1408745","article-title":"Monocytes\/Macrophages promote vascular CXCR4 expression via the ERK pathway in hepatocellular carcinoma.","volume":"7","author":"Zheng","year":"2018","journal-title":"Oncoimmunology"},{"key":"103","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.canlet.2016.08.004","article-title":"Macrophages induce resistance to 5-fluorouracil chemotherapy in colorectal cancer through the release of putrescine.","volume":"38","author":"Liang","year":"2016","journal-title":"Cancer Lett"},{"key":"104","doi-asserted-by":"publisher","first-page":"3051","DOI":"10.2147\/OTT.S198126","article-title":"M2 macrophages confer resistance to 5-fluorouracil in colorectal cancer through the activation of CCL22\/PI3K\/AKT signaling.","volume":"1","author":"Xiong","year":"2019","journal-title":"Onco Targets Ther"},{"key":"105","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1016\/j.cmet.2019.02.001","article-title":"Macrophage-Released Pyrimidines Inhibit Gemcitabine Therapy in Pancreatic Cancer.","volume":"2","author":"Nelson","year":"2019","journal-title":"Cell Metab"},{"key":"106","doi-asserted-by":"publisher","first-page":"219","DOI":"10.3390\/biomedicines10020219","article-title":"Macrophage C\/EBP\u03b4 Drives Gemcitabine, but Not 5-FU or Paclitaxel, Resistance of Pancreatic Cancer Cells in a Deoxycytidine-Dependent Manner.","volume":"1","author":"Duitman","year":"2022","journal-title":"Biomedicines"},{"key":"107","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s12935-019-0771-8","article-title":"Tumor-associated macrophages modulate resistance to oxaliplatin via inducing autophagy in hepatocellular carcinoma.","volume":"1","author":"Fan","year":"2019","journal-title":"Cancer Cell Int"},{"key":"108","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1038\/s41467-020-14642-0","article-title":"Heterogeneity of response to immune checkpoint blockade in hypermutated experimental gliomas.","volume":"1","author":"Sanghvi","year":"2020","journal-title":"Nat Commun"},{"key":"109","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1186\/s13045-021-01207-x","article-title":"Amplification of spatially isolated adenosine pathway by tumor-macrophage interaction induces anti-PD1 resistance in hepatocellular carcinoma.","volume":"1","author":"Ke","year":"2021","journal-title":"J Hematol Oncol"},{"key":"110","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1158\/1078-0432.CCR-19-1868","article-title":"Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade.","volume":"2","author":"Gide","year":"2020","journal-title":"Clin Cancer Res"},{"key":"111","doi-asserted-by":"publisher","first-page":"2596","DOI":"10.1038\/s41388-021-01734-4","article-title":"Epiregulin confers EGFR-TKI resistance via EGFR\/ErbB2 heterodimer in non-small cell lung cancer.","volume":"4","author":"Cao","year":"2021","journal-title":"Oncogene"},{"key":"112","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1158\/1078-0432.CCR-15-2597","article-title":"Progression of EGFR-Mutant Lung Adenocarcinoma is Driven By Alveolar Macrophages.","volume":"2","author":"Burt","year":"2017","journal-title":"Clin Cancer Res"},{"key":"113","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1038\/s41419-020-03161-x","article-title":"Tumor necrosis factor \u03b1 inhibition overcomes immunosuppressive M2b macrophage-induced bevacizumab resistance in triple-negative breast cancer.","volume":"1","author":"Yang","year":"2020","journal-title":"Cell Death Dis"},{"key":"114","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s40478-021-01163-0","article-title":"TNF\u03b1 secreted by glioma associated macrophages promotes endothelial activation and resistance against anti-angiogenic therapy.","volume":"9","author":"Zadeh","year":"2021","journal-title":"Acta Neuropathol Commun"},{"key":"115","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.mam.2011.04.005","article-title":"Macrophage regulation of tumor angiogenesis: implications for cancer therapy.","volume":"3","author":"De Palma","year":"2011","journal-title":"Mol Aspects Med"},{"key":"116","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neo.2016.11.010","article-title":"SDF-1 Blockade Enhances Anti-VEGF Therapy of Glioblastoma and Can Be Monitored by MRI.","volume":"1","author":"Martin Brown","year":"2017","journal-title":"Neoplasia"},{"key":"117","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1126\/science.1178331","article-title":"Development of monocytes, macrophages, and dendritic cells.","volume":"32","author":"Ley","year":"2010","journal-title":"Science"},{"key":"118","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/ni.3324","article-title":"New insights into the multidimensional concept of macrophage ontogeny, activation and function.","volume":"1","author":"Biswas","year":"2016","journal-title":"Nat Immunol"},{"key":"119","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.canlet.2020.10.043","article-title":"TD-92, a novel erlotinib derivative, depletes tumor-associated macrophages in non-small cell lung cancer via down-regulation of CSF-1R and enhances the anti-tumor effects of anti-PD-1.","volume":"49","author":"Chen","year":"2021","journal-title":"Cancer Lett"},{"key":"120","doi-asserted-by":"publisher","first-page":"96496","DOI":"10.18632\/oncotarget.20410","article-title":"Macrophage depletion through colony stimulating factor 1 receptor pathway blockade overcomes adaptive resistance to anti-VEGF therapy.","volume":"8","author":"Mak","year":"2017","journal-title":"Oncotarget"},{"key":"121","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s11523-014-0320-2","article-title":"Carlumab, an anti-C-C chemokine ligand 2 monoclonal antibody, in combination with four chemotherapy regimens for the treatment of patients with solid tumors: an open-label, multicenter phase 1b study.","volume":"1","author":"Calvo","year":"2015","journal-title":"Target Oncol"},{"key":"122","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1007\/s00280-013-2099-8","article-title":"A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors.","volume":"7","author":"Tolcher","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"key":"123","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1007\/s10637-012-9869-8","article-title":"Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer.","volume":"3","author":"de Bono","year":"2013","journal-title":"Invest New Drugs"},{"key":"124","doi-asserted-by":"publisher","first-page":"10455","DOI":"10.1073\/pnas.1710754114","article-title":"Targeting CXCR4-dependent immunosuppressive Ly6C(low) monocytes improves antiangiogenic therapy in colorectal cancer.","volume":"11","author":"Willett","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"key":"125","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/j.ccr.2011.04.016","article-title":"Receptor tyrosine kinases and TLR\/IL1Rs unexpectedly activate myeloid cell PI3k\u03b3, a single convergent point promoting tumor inflammation and progression.","volume":"1","author":"Cheresh","year":"2011","journal-title":"Cancer Cell"},{"key":"126","doi-asserted-by":"publisher","first-page":"e2009290118","DOI":"10.1073\/pnas.2009290118","article-title":"PI3K\u03b3 inhibition suppresses microglia\/TAM accumulation in glioblastoma microenvironment to promote exceptional temozolomide response.","volume":"11","author":"Zhu","year":"2021","journal-title":"Proc Natl Acad Sci U S A"},{"key":"127","doi-asserted-by":"publisher","first-page":"1900327","DOI":"10.1002\/advs.201900327","article-title":"PI3Kgamma Inhibitor Attenuates Immunosuppressive Effect of Poly(l-Glutamic Acid)-Combretastatin A4 Conjugate in Metastatic Breast Cancer.","volume":"6","author":"Chen","year":"2019","journal-title":"Adv Sci (Weinh)"},{"key":"128","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.3389\/fimmu.2018.01650","article-title":"TLR-3 Stimulation Skews M2 Macrophages to M1 Through IFN-\u03b1\u03b2 Signaling and Restricts Tumor Progression.","volume":"9","author":"Agrewala","year":"2018","journal-title":"Front Immunol"},{"key":"129","doi-asserted-by":"publisher","first-page":"e002408","DOI":"10.1136\/jitc-2021-002408","article-title":"Intratumoral combination therapy with poly(I:C) and resiquimod synergistically triggers tumor-associated macrophages for effective systemic antitumoral immunity.","volume":"9","author":"Calvo","year":"2021","journal-title":"J Immunother Cancer"},{"key":"130","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.canlet.2019.10.020","article-title":"TLR 7\/8 agonist reverses oxaliplatin resistance in colorectal cancer via directing the myeloid-derived suppressor cells to tumoricidal M1-macrophages.","volume":"46","author":"Wang","year":"2020","journal-title":"Cancer Lett"},{"key":"131","doi-asserted-by":"publisher","first-page":"12579","DOI":"10.1021\/jacs.0c05039","article-title":"Nanoscale Metal-Organic Framework Co-delivers TLR-7 Agonists and Anti-CD47 Antibodies to Modulate Macrophages and Orchestrate Cancer Immunotherapy.","volume":"14","author":"Lin","year":"2020","journal-title":"J Am Chem Soc"},{"key":"132","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1158\/1078-0432.CCR-12-2064","article-title":"Agonistic CD40 antibodies and cancer therapy.","volume":"1","author":"Glennie","year":"2013","journal-title":"Clin Cancer Res"},{"key":"133","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1126\/science.1198443","article-title":"CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans.","volume":"33","author":"Vonderheide","year":"2011","journal-title":"Science"},{"key":"134","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1007\/s00262-013-1427-5","article-title":"CD40 immunotherapy for pancreatic cancer.","volume":"6","author":"Beatty","year":"2013","journal-title":"Cancer Immunol Immunother"},{"key":"135","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1158\/2326-6066.CIR-17-0345","article-title":"Macrophages and CD8T Cells Mediate the Antitumor Efficacy of Combined CD40 Ligation and Imatinib Therapy in Gastrointestinal Stromal Tumors.","volume":"6","author":"Balachandran","year":"2018","journal-title":"Cancer Immunol Res"},{"key":"136","doi-asserted-by":"publisher","first-page":"111462","DOI":"10.1016\/j.celrep.2022.111462","article-title":"PARP-inhibition reprograms macrophages toward an anti-tumor phenotype.","volume":"4","author":"Cyr","year":"2022","journal-title":"Cell Rep"},{"key":"137","doi-asserted-by":"publisher","first-page":"121790","DOI":"10.1016\/j.lfs.2023.121790","article-title":"PARP inhibition synergizes with CD47 blockade to promote phagocytosis by tumor-associated macrophages in homologous recombination-proficient tumors.","volume":"32","author":"Zhang","year":"2023","journal-title":"Life Sci"},{"key":"138","doi-asserted-by":"publisher","first-page":"265","DOI":"10.7150\/thno.27246","article-title":"Targeting lipid metabolism to overcome EMT-associated drug resistance via integrin \u03b23\/FAK pathway and tumor-associated macrophage repolarization using legumain-activatable delivery.","volume":"9","author":"Huang","year":"2019","journal-title":"Theranostics"},{"key":"139","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.4049\/jimmunol.175.4.2071","article-title":"Both dendritic cells and macrophages can stimulate naive CD8 T cells in vivo to proliferate, develop effector function, and differentiate into memory cells.","volume":"17","author":"Rock","year":"2005","journal-title":"J Immunol"},{"key":"140","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1038\/nature12034","article-title":"Macrophage biology in development, homeostasis and disease.","volume":"49","author":"Pollard","year":"2013","journal-title":"Nature"},{"key":"141","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/j.molmed.2018.03.006","article-title":"Macrophages: The Road Less Traveled, Changing Anticancer Therapy.","volume":"2","author":"Guerriero","year":"2018","journal-title":"Trends Mol Med"},{"key":"142","doi-asserted-by":"publisher","first-page":"5728","DOI":"10.1158\/0008-5472.CAN-09-4672","article-title":"Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes.","volume":"7","author":"Van Ginderachter","year":"2010","journal-title":"Cancer Res"},{"key":"143","doi-asserted-by":"publisher","first-page":"7465","DOI":"10.1158\/0008-5472.CAN-10-1439","article-title":"Macrophage expression of hypoxia-inducible factor-1 alpha suppresses T-cell function and promotes tumor progression.","volume":"7","author":"Johnson","year":"2010","journal-title":"Cancer Res"},{"key":"144","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/j.ccell.2014.09.006","article-title":"Macrophage IL-10 blocks CD8+ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells.","volume":"2","author":"Coussens","year":"2014","journal-title":"Cancer Cell"},{"key":"145","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1111\/j.1365-2567.2005.02312.x","article-title":"Peritoneal macrophages suppress T-cell activation by amino acid catabolism.","volume":"11","author":"Riggs","year":"2006","journal-title":"Immunology"},{"key":"146","doi-asserted-by":"publisher","first-page":"257","DOI":"10.2174\/1381612033392026","article-title":"Macrophages and the regulation of self-reactive T cells.","volume":"9","author":"Mellor","year":"2003","journal-title":"Curr Pharm Des"},{"key":"147","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.ebiom.2017.07.014","article-title":"A Natural CCR2 Antagonist Relieves Tumor-associated Macrophage-mediated Immunosuppression to Produce a Therapeutic Effect for Liver Cancer.","volume":"2","author":"Wang","year":"2017","journal-title":"EBioMedicine"},{"key":"148","doi-asserted-by":"publisher","first-page":"e2024171118","DOI":"10.1073\/pnas.2024171118","article-title":"CCRL2 promotes antitumor T-cell immunity via amplifying TLR4-mediated immunostimulatory macrophage activation.","volume":"11","author":"He","year":"2021","journal-title":"Proc Natl Acad Sci U S A"},{"key":"149","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1158\/1535-7163.MCT-20-0591","article-title":"CSF1\/CSF1R Signaling Inhibitor Pexidartinib (PLX3397) Reprograms Tumor-Associated Macrophages and Stimulates T-cell Infiltration in the Sarcoma Microenvironment.","volume":"2","author":"Moore","year":"2021","journal-title":"Mol Cancer Ther"},{"key":"150","doi-asserted-by":"publisher","first-page":"e2015433118","DOI":"10.1073\/pnas.2015433118","article-title":"A highly selective and potent CXCR4 antagonist for hepatocellular carcinoma treatment.","volume":"11","author":"Lee","year":"2021","journal-title":"Proc Natl Acad Sci U S A"},{"key":"151","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/nature20554","article-title":"Overcoming resistance to checkpoint blockade therapy by targeting PI3K\u03b3 in myeloid cells.","volume":"53","author":"Sharma","year":"2016","journal-title":"Nature"},{"key":"152","doi-asserted-by":"publisher","first-page":"4253","DOI":"10.1158\/0008-5472.CAN-17-3876","article-title":"Macrophage-Derived Granulin Drives Resistance to Immune Checkpoint Inhibition in Metastatic Pancreatic Cancer.","volume":"7","author":"Schmid","year":"2018","journal-title":"Cancer Res"},{"key":"153","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/nature19834","article-title":"PI3K\u03b3 is a molecular switch that controls immune suppression.","volume":"53","author":"Winkler","year":"2016","journal-title":"Nature"},{"key":"154","doi-asserted-by":"publisher","first-page":"E4041","DOI":"10.1073\/pnas.1720948115","article-title":"Macrophages impede CD8 T cells from reaching tumor cells and limit the efficacy of anti-PD-1 treatment.","volume":"11","author":"Alifano","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"155","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1038\/s41586-019-1456-0","article-title":"CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy.","volume":"57","author":"Weissman","year":"2019","journal-title":"Nature"},{"key":"156","doi-asserted-by":"publisher","first-page":"882","DOI":"10.3390\/vaccines9080882","article-title":"Anti-CD47 Monoclonal Antibody-Drug Conjugate: A Targeted Therapy to Treat Triple-Negative Breast Cancers.","volume":"9","author":"Liu","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"157","doi-asserted-by":"publisher","first-page":"e2026849118","DOI":"10.1073\/pnas.2026849118","article-title":"Combining CD47 blockade with trastuzumab eliminates HER2-positive breast cancer cells and overcomes trastuzumab tolerance.","volume":"11","author":"Weissman","year":"2021","journal-title":"Proc Natl Acad Sci U S A"},{"key":"158","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s00018-021-04124-x","article-title":"ZBTB28 inhibits breast cancer by activating IFNAR and dual blocking CD24 and CD47 to enhance macrophages phagocytosis.","volume":"7","author":"Luo","year":"2022","journal-title":"Cell Mol Life Sci"},{"key":"159","doi-asserted-by":"publisher","first-page":"e6","DOI":"10.1038\/bcj.2011.5","article-title":"Human glioblastoma cells exposed to long-term hypoxia and nutrient starvation stimulated induction of secondary T-cell leukemia in mice.","volume":"1","author":"Shibuya","year":"2011","journal-title":"Blood Cancer J"},{"key":"160","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1111\/j.1349-7006.2009.01105.x","article-title":"Hypoxia and low-nutrition double stress induces aggressiveness in a murine model of melanoma.","volume":"10","author":"Shibuya","year":"2009","journal-title":"Cancer Sci"},{"key":"161","doi-asserted-by":"publisher","first-page":"3019","DOI":"10.1158\/0008-5472.CAN-12-3231","article-title":"Inhibition of histone demethylase JMJD1A improves anti-angiogenic therapy and reduces tumor-associated macrophages.","volume":"7","author":"Shibuya","year":"2013","journal-title":"Cancer Res"},{"key":"162","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1200\/JCO.2014.55.9575","article-title":"Lessons from anti-vascular endothelial growth factor and anti-vascular endothelial growth factor receptor trials in patients with glioblastoma.","volume":"3","author":"Jain","year":"2015","journal-title":"J Clin Oncol"},{"key":"163","doi-asserted-by":"publisher","first-page":"3212","DOI":"10.1200\/JCO.2012.47.2464","article-title":"Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma.","volume":"3","author":"Cher","year":"2013","journal-title":"J Clin Oncol"},{"key":"164","doi-asserted-by":"publisher","first-page":"2817","DOI":"10.1200\/JCO.2009.26.3988","article-title":"Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma.","volume":"2","author":"Chea","year":"2010","journal-title":"J Clin Oncol"},{"key":"165","doi-asserted-by":"publisher","first-page":"4470","DOI":"10.1073\/pnas.1525349113","article-title":"Dual inhibition of Ang-2 and VEGF receptors normalizes tumor vasculature and prolongs survival in glioblastoma by altering macrophages.","volume":"11","author":"Snuderl","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"166","doi-asserted-by":"publisher","first-page":"4476","DOI":"10.1073\/pnas.1525360113","article-title":"Ang-2\/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival.","volume":"11","author":"Lu-Emerson","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"167","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/S0140-6736(19)30764-0","article-title":"Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial.","volume":"39","author":"Healey","year":"2019","journal-title":"Lancet"},{"key":"168","doi-asserted-by":"publisher","first-page":"5519","DOI":"10.1158\/1078-0432.CCR-21-1779","article-title":"A Phase I Study of the Combination of Pexidartinib and Sirolimus to Target Tumor-Associated Macrophages in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath Tumors.","volume":"2","author":"Schwartz","year":"2021","journal-title":"Clin Cancer Res"},{"key":"169","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1056\/NEJMoa1411366","article-title":"Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor.","volume":"37","author":"Puzanov","year":"2015","journal-title":"N Engl J Med"},{"key":"170","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.ejca.2020.09.038","article-title":"Long-term clinical activity, safety and patient-reported quality of life for emactuzumab-treated patients with diffuse-type tenosynovial giant-cell tumour.","volume":"14","author":"Watson","year":"2020","journal-title":"Eur J Cancer"},{"key":"171","doi-asserted-by":"publisher","first-page":"e004076","DOI":"10.1136\/jitc-2021-004076","article-title":"Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients na\u00efve or experienced for immune checkpoint blockade.","volume":"1","author":"Mcdermott","year":"2022","journal-title":"J Immunother Cancer"},{"key":"172","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1093\/annonc\/mdz163","article-title":"Phase I study of emactuzumab single agent or in combination with paclitaxel in patients with advanced\/metastatic solid tumors reveals depletion of immunosuppressive M2-like macrophages.","volume":"3","author":"Christen","year":"2019","journal-title":"Ann Oncol"},{"key":"173","doi-asserted-by":"publisher","first-page":"e001153","DOI":"10.1136\/jitc-2020-001153","article-title":"Phase Ib study of anti-CSF-1R antibody emactuzumab in combination with CD40 agonist selicrelumab in advanced solid tumor patients.","volume":"8","author":"Korski","year":"2020","journal-title":"J Immunother Cancer"},{"key":"174","doi-asserted-by":"publisher","first-page":"3486","DOI":"10.1158\/1078-0432.CCR-18-2994","article-title":"Surufatinib in Advanced Well-Differentiated Neuroendocrine Tumors: A Multicenter, Single-Arm, Open-Label, Phase Ib\/II Trial.","volume":"2","author":"Cheng","year":"2019","journal-title":"Clin Cancer Res"},{"key":"175","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1158\/1078-0432.CCR-21-3009","article-title":"ARRY-382 in Combination with Pembrolizumab in Patients with Advanced Solid Tumors: Results from a Phase 1b\/2 Study.","volume":"2","author":"Goldman","year":"2022","journal-title":"Clin Cancer Res"},{"key":"176","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.ejca.2022.03.017","article-title":"Pembrolizumab and maraviroc in refractory mismatch repair proficient\/microsatellite-stable metastatic colorectal cancer - The PICCASSO phase I trial.","volume":"16","author":"Al-Batran","year":"2022","journal-title":"Eur J Cancer"},{"key":"177","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1002\/ijc.32141","article-title":"First-in-human study with intratumoral administration of a CD40 agonistic antibody, ADC-1013, in advanced solid malignancies.","volume":"14","author":"Ullenhag","year":"2019","journal-title":"Int J Cancer"},{"key":"178","doi-asserted-by":"publisher","first-page":"4574","DOI":"10.1158\/1078-0432.CCR-21-1047","article-title":"Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer.","volume":"2","author":"Park","year":"2021","journal-title":"Clin Cancer Res"},{"key":"179","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1038\/s41591-022-01829-9","article-title":"Sotigalimab and\/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial.","volume":"2","author":"Pfeiffer","year":"2022","journal-title":"Nat Med"},{"key":"180","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1182\/blood-2017-05-786566","article-title":"Duvelisib, a novel oral dual inhibitor of PI3K-\u03b4,\u03b3, is clinically active in advanced hematologic malignancies.","volume":"13","author":"Douglas","year":"2018","journal-title":"Blood"},{"key":"181","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1158\/1078-0432.CCR-17-0357","article-title":"Phase Ib Study of Immune Biomarker Modulation with Neoadjuvant Cetuximab and TLR8 Stimulation in Head and Neck Cancer to Overcome Suppressive Myeloid Signals.","volume":"2","author":"Ferris","year":"2018","journal-title":"Clin Cancer Res"},{"key":"182","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/j.ijrobp.2020.02.639","article-title":"BRAINSTORM: A Multi-Institutional Phase 1\/2 Study of RRx-001 in Combination With Whole Brain Radiation Therapy for Patients With Brain Metastases.","volume":"10","author":"Lawrence","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"183","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1080\/13543784.2021.1863947","article-title":"Results from a biomarker study to accompany a phase II trial of RRx-001 with reintroduced platinum-based chemotherapy in relapsed small cell carcinoma.","volume":"3","author":"Trepel","year":"2021","journal-title":"Expert Opin Investig Drugs"},{"key":"184","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.clcc.2022.11.003","article-title":"ROCKET: Phase II Randomized, Active-controlled, Multicenter Trial to Assess the Safety and Efficacy of RRx-001 + Irinotecan vs. Single-agent Regorafenib in Third\/Fourth Line Colorectal Cancer.","volume":"2","author":"Fisher","year":"2023","journal-title":"Clin Colorectal Cancer"},{"key":"185","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1056\/NEJMoa1807315","article-title":"CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma.","volume":"37","author":"Chen","year":"2018","journal-title":"N Engl J Med"},{"key":"186","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1200\/JCO.18.02018","article-title":"First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers.","volume":"3","author":"Prohaska","year":"2019","journal-title":"J Clin Oncol"},{"key":"187","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1158\/1078-0432.CCR-20-3706","article-title":"Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies.","volume":"2","author":"Mei","year":"2021","journal-title":"Clin Cancer Res"},{"key":"188","doi-asserted-by":"publisher","first-page":"e002015","DOI":"10.1136\/jitc-2020-002015","article-title":"Phase I study of ABBV-428, a mesothelin-CD40 bispecific, in patients with advanced solid tumors.","volume":"9","author":"Kindler","year":"2021","journal-title":"J Immunother Cancer"},{"key":"189","doi-asserted-by":"publisher","first-page":"4757","DOI":"10.1158\/1078-0432.CCR-21-0903","article-title":"A Phase I Study of APX005M and Cabiralizumab with or without Nivolumab in Patients with Melanoma, Kidney Cancer, or Non-Small Cell Lung Cancer Resistant to Anti-PD-1\/PD-L1.","volume":"2","author":"Mahajan","year":"2021","journal-title":"Clin Cancer Res"}],"container-title":["Aging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.aging-us.com\/lookup\/doi\/10.18632\/aging.205858","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T10:53:09Z","timestamp":1718880789000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aging-us.com\/lookup\/doi\/10.18632\/aging.205858"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,23]]},"references-count":189,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,6,15]]}},"alternative-id":["205858","38787372"],"URL":"https:\/\/doi.org\/10.18632\/aging.205858","relation":{},"ISSN":["1945-4589"],"issn-type":[{"value":"1945-4589","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,23]]}}}